Today: 8 June 2026
Browse Category

NYSE:BMY 15 October 2025 - 23 December 2025

Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb closed at $54.66 Monday, up 0.87%, and traded near $54.75 after hours. Investors are watching the company’s new agreement with the Trump administration, which includes providing Eliquis free to Medicaid from 2026 and donating active pharmaceutical ingredients. The deal grants BMS three years of tariff relief, with further pricing terms kept confidential.
23 December 2025
··
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bank of America upgraded Bristol-Myers Squibb to “Buy” on Dec. 16, raising its price target to $61. BMY shares traded at $53.66, down 1.15% as of 2:00 p.m. Institutional interest increased, with Shorepoint Capital Partners opening a new position. Analysts cited strong Q3 results and a pipeline of 2026 catalysts as factors in the valuation debate.
16 December 2025
·
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb shares rose 3.6% to $54.29 on December 16 after Bank of America upgraded the stock to Buy and raised its price target to $61, citing confidence in the company’s R&D pipeline. The board also increased the quarterly dividend to $0.63 per share, payable February 2, 2026, marking a 1.6% annual increase and the 17th consecutive yearly hike.
16 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb shares rose 3.6% to $54.29 Monday after Bank of America upgraded the stock to Buy and raised its price target to $61. The stock added another 0.6% in after-hours trading. Volume in extended trading reached about 1.25 million shares. Analysts cited the company’s R&D pipeline and upcoming catalysts as key drivers.
16 December 2025
··
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb shares rose 2.5% to $52.50 by mid-day Friday after Guggenheim upgraded the stock to Buy with a $62 target. The company announced a 1.6% dividend increase to $0.63 per share, its 17th consecutive annual raise. The FDA granted Priority Review for Opdivo in Hodgkin lymphoma, and approved Breyanzi for marginal zone lymphoma earlier this month.
12 December 2025
·
Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb shares closed at $52.15 on December 5, 2025, after a week marked by a surprise Alzheimer’s drug trial update, major hematology data, and a legal setback. The stock rebounded 7% over several days, adding $7 billion in market value. BMY trades at a trailing P/E of 17.5x with a 4.7–5% dividend yield. Analyst consensus rates the stock a hold, with modest upside expected.
7 December 2025
·
Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb shares rallied this week, trading near $50.55 after news on its Alzheimer’s drug Cobenfy, an AI drug discovery milestone, and a key lawsuit ruling. The company declared a $0.62 quarterly dividend, bringing the annual yield to about 4.9%. Market cap stands at $104 billion. Despite the rebound, BMY shares remain down roughly 15% for 2025.
4 December 2025
··
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb shares jumped over 6% to $51.32 intraday on December 3, 2025, after the company announced a data review and patient re-enrollment for its ADEPT-2 Alzheimer’s psychosis trial. The stock rally follows strong Q3 results and analyst upgrades, despite ongoing legal risks and looming patent expiries.
3 December 2025
····
Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

A U.S. judge on Dec. 1, 2025, revived a $6.7 billion lawsuit against Bristol-Myers Squibb over Celgene contingent value rights, sending BMY shares down 1.89% to $48.25. The stock marked its third straight loss, underperforming peers as legal risks weighed despite positive hematology data at ASH 2025. Market cap stood at about $98 billion. Trading volume was below average at 14.5 million shares.
3 December 2025
··
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

A U.S. federal judge allowed a $6.7 billion lawsuit against Bristol-Myers Squibb over its 2019 Celgene acquisition to proceed, rejecting the company’s motion to dismiss key claims. BMY shares closed at $49.18 on December 1, up 7–8% over five days, but remain down for the year. The company’s annual dividend yield is about 5%. New cell therapy approvals and strong ASH 2025 hematology data also drew investor attention.
2 December 2025
·
Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb closed November 28 at $49.20, down 22% from its March high and trailing the S&P 500 by over 30 percentage points year-to-date. The stock’s 5.4% dividend yield drew headlines November 29, as analysts maintained “Hold” ratings and institutional investors quietly increased stakes. Valuation metrics show BMY trading at steep discounts to pharma peers.
30 November 2025
··
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Bristol Myers Squibb shares rose 4.3% to $48.24 Monday after renewed investor interest in Factor XIa blood-thinner drugs and its candidate milvexian. The company announced a hematology-focused virtual investor event for December 11. Despite the gain, BMY remains down about 14% for the year, trailing the S&P 500’s 13.6% rise. Q3 earnings beat expectations, with revenue up 3% to $12.2 billion.
24 November 2025
·
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson have halted the Phase 3 Librexia ACS trial of milvexian in acute coronary syndrome after an interim review showed the drug was unlikely to meet its main efficacy goal. BMY shares fell following the announcement. No new safety issues were reported. The trial had aimed to enroll about 16,000 patients worldwide.
14 November 2025
···
5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

Walmart shares dropped up to 3% after the company named John Furner as CEO, replacing Doug McMillon effective February 2026. Merck agreed to buy Cidara Therapeutics for $9.2 billion in cash, gaining access to a late-stage flu prevention drug. U.S. equity futures fell sharply as tech stocks continued to slide and traders lowered expectations for a near-term Fed rate cut.
14 November 2025
·····
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol Myers Squibb priced €5 billion in senior notes across five tranches, with closing expected Nov. 10; proceeds will fund a debt tender offer running through Dec. 3. The company agreed to a $239 million settlement in a Celgene class action, pending court approval. BioNTech raised its 2025 revenue outlook after receiving payments from a new BMS alliance. FDA approved a generic for Sprycel on Nov. 7.
9 November 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb reported Q3 adjusted EPS of $1.63 on $12.2 billion revenue, beating estimates, and raised its 2025 outlook. Shares rebounded 3–4% after hitting a 52-week low, with dividend yield now near 5.5%. New drugs like Opdivo and Eliquis outperformed, offsetting a sharp Revlimid decline. The company acquired Orbital Therapeutics and launched schizophrenia drug Cobenfy, posting $62 million in early sales.
30 October 2025
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 15.10.2025

Bristol-Myers Squibb (BMY) scored 88% under Validea’s Partha Mohanram P/B Growth Investor model, the highest among 22 strategies reviewed. Most key financial tests passed, but the stock failed the research and development to assets metric.
15 October 2025
·
1 2 3

Stock Market Today

  • Cerebras Surge Highlights Ongoing AI Chip Demand, ASX Investors Eye Local Alternatives
    June 8, 2026, 4:08 PM EDT. Cerebras, a notable Nvidia competitor, soared over 20% after its recent Nasdaq debut and strong 2025 financials including a US$20 billion+ deal with OpenAI. Despite last week's AI chip sell-off wiping US$1.3 trillion off sector value, the rebound indicates sustained demand for AI hardware. While Cerebras isn't available on the ASX, local high-risk, early-stage players like BrainChip, Weebit Nano, and Archer Materials offer Australian investors exposure to AI chip innovation. Cerebras' rapid revenue growth (76% to US$510 million) and turnaround to profit underline robust AI compute market prospects.

Latest articles

Tesla Stock Bounces Over $400 After China Sales Beat—But There’s a Caveat

Tesla Stock Bounces Over $400 After China Sales Beat—But There’s a Caveat

8 June 2026
Tesla shares soared over 5% to $411.66 after a China sales report showed May retail sales up 22.5%, ending a two-month decline, and J.P. Morgan upgraded the stock, citing rising value from autonomy and software; the rally outpaced the Nasdaq as investors bet on Tesla’s China resilience and technology story despite a lofty price-to-earnings ratio of about 378.
Ondas Stock Comes Back Into the Spotlight After 13% Drop; Drone Trade Faces Fresh Challenge

Ondas Stock Comes Back Into the Spotlight After 13% Drop; Drone Trade Faces Fresh Challenge

8 June 2026
Ondas shares slipped 0.5% to $10.38 as investors weighed a new $4.8M U.S. Navy-linked balloon contract and $110M in Q2 orders against high short interest (31.33% of float), rising operating losses, and fresh stock-supply concerns after a June 3 filing revealed more Omnisys-related shares could hit the market, raising dilution risks despite surging revenue and backlog.
Archer Aviation Shares Bounce Back, FAA Timeline and Cash Burn in Focus

Archer Aviation Shares Bounce Back, FAA Timeline and Cash Burn in Focus

8 June 2026
Archer Aviation shares jumped 4.2% to $5.77 after last week’s 13.2% drop, as investors rotated back into growth and air-taxi stocks; the move follows Archer’s milestone as the first eVTOL developer to close Phase 3 of FAA certification, but heavy losses and high cash burn keep the stock highly sensitive to regulatory and financial risks.
Galaxy Digital spikes 24% as investors look at AI data center plans

Galaxy Digital spikes 24% as investors look at AI data center plans

8 June 2026
Galaxy Digital shares soared 23.6% to $31.07 after CEO Mike Novogratz said its West Texas AI data center—half of which is already leased—now represents more than half the company’s value, shifting focus from crypto to AI infrastructure; the stock’s surge outpaced bitcoin’s 2.7% rise as investors repriced Galaxy’s data-center business amid execution risks and strong analyst buy ratings.
Go toTop